22nd Century Group, Inc. — Cyborg Score 4/10

Mixed
Tobacco Products / Biotechnology - Plant Science (Nicotine Harm Reduction)

Strategic Profile

With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the business. The company recently secured a 5-year agreement with Smoker Friendly that includes manufacturing 11 existing brands and launching 8 new premium brands. The company is positioned to benefit from potential FDA-mandated reduced nicotine standards in the tobacco industry.

Cyborg Score Rationale

The company reports revenue of $7.84 million with no growth over the past three years. Financial health grades indicate distress, with a Z-Score in the distress zone. However, strong patent IP and recent manufacturing partnerships provide potential upside catalysts if reduced nicotine regulations are implemented.

Top Insights

  • VLN® is FDA-approved as a Modified Risk Tobacco Product (MRTP), providing regulatory differentiation in a highly restricted industry
  • Extensive patent portfolio providing IP protection for nicotine-reduction technology across multiple jurisdictions through 2042
  • Contract manufacturing relationships with third-party brands (Smoker Friendly 5-year deal announced May 2025) diversifies revenue and derisks dependency on own branded sales
  • Potential exposure to FDA nicotine reduction mandate could be transformative, though execution on manufacturing scale-up presents capital and operational risks

Named Competitors

  • Traditional Combustible Cigarettes — Large-scale conventional tobacco manufacturers with established distribution networks
  • Alternative Nicotine Delivery (e-cigarettes, pouches, snus) — Non-combustible nicotine delivery systems competing for smoker switching

Recent Developments

  • (May 2025) Expanded manufacturing agreement with Smoker Friendly: 11 existing brands + 8 new premium brands over 5-year term
  • (January 2025) Announced readiness to support FDA's proposed reduced nicotine cigarette policy implementation
  • (November 2023) Signed exclusive reduced nicotine content technology license with North Carolina State University extending IP portfolio through 2042

Open the full interactive 22nd Century Group, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →